147 related articles for article (PubMed ID: 26707267)
1. Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Vokó Z; Akhras KS; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):15-6. PubMed ID: 26707267
[No Abstract] [Full Text] [Related]
2. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
Carapinha JL
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
[TBL] [Abstract][Full Text] [Related]
3. Implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
[TBL] [Abstract][Full Text] [Related]
4. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
Danzon PM
Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
[TBL] [Abstract][Full Text] [Related]
5. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
6. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
7. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
Holtorf AP; Gialama F; Wijaya KE; Kaló Z
Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
[TBL] [Abstract][Full Text] [Related]
8. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
9. Assessing the impact of global price interdependencies.
Richter A
Pharmacoeconomics; 2008; 26(8):649-59. PubMed ID: 18620459
[TBL] [Abstract][Full Text] [Related]
10. Review of studies reporting actual prices for medicines.
Mardetko N; Kos M; Vogler S
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
[TBL] [Abstract][Full Text] [Related]
11. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
Elek P; Takács E; Merész G; Kaló Z
Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
[TBL] [Abstract][Full Text] [Related]
12. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
[TBL] [Abstract][Full Text] [Related]
13. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
Hertzman P; Miller P; Tolley K
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
[TBL] [Abstract][Full Text] [Related]
14. Effects of regulation on drug launch and pricing in interdependent markets.
Danzon PM; Epstein AJ
Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
[TBL] [Abstract][Full Text] [Related]
15. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
[TBL] [Abstract][Full Text] [Related]
16. Impact of parallel trade on pharmaceutical firm's profits: rise or fall?
Guo S; Hu B; Zhong H
Eur J Health Econ; 2013 Apr; 14(2):345-55. PubMed ID: 22286662
[TBL] [Abstract][Full Text] [Related]
17. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
18. The economics of parallel trade.
Danzon PM
Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
[TBL] [Abstract][Full Text] [Related]
19. Measuring the Value of Pharmaceuticals in the US Health System.
Walton SM; Basu A; Mullahy J; Hong S; Schumock GT
Pharmacoeconomics; 2017 Jan; 35(1):1-4. PubMed ID: 27785770
[No Abstract] [Full Text] [Related]
20. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
